Treatment with Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multicenter Phase 2b Clinical Trial (STAT).

In terms of secondary outcomes, in the entire cohort of 120 patients, those treated with MSCs had significantly fewer ventilator-free days and fewer ICU-free days; however, in the COVID-19 cohort, the numerically fewer ventilator-free days and ICU-free days did not reach statistical significance ( Table 3 ).

also in 111,027 other papers